EML4-ALK fusion gene in korean non-small cell lung cancer

Journal of Korean Medical Science

Volumn 27, Issue 2, 2012, Pages 228-230

  Jin, Guang ^a   Jeon, Hyo Sung ^a   Lee, Eung Bae ^a   Kang, Hyo Gyoung ^a   Yoo, Seung Soo ^a   Lee, Shin Yup ^a   Lee, Jae Hee ^a   Cha, Sung Ick ^a   Park, Tae In ^a   Kim, Chang Ho ^a   Jheon, Sang Hoon ^b   Park, Jae Yong ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

ALK; Carcinoma; EML4; Non small cell lung

Indexed keywords

EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; ASIAN; CHEMISTRY; EXON; FEMALE; GENETICS; HUMAN; INTRON; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SMOKING; SOUTH KOREA;

ADENOCARCINOMA; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; HUMANS; INTRONS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, RNA; SMOKING;

EID: 84863116225     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.2.228     Document Type: Article

References (16)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25: 1113-21.
3. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009; 24: 995-1003.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
5. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67: 257-74.
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007; 448: 561-6.
7. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46: 1773-80.
8. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-83.
9. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-95.
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010; 363: 1693-703.
11. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010; 36: S21-9.
12. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small cell lung cancer. J Clin Oncol 2009; 27: 4232-5.
13. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH. Detection of ALK gene rearrangement in nonsmall cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011; 6: 1359-66.
14. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC. Distinct clinical features and outcomes in never-smokers with non-small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2011. Doi:10.1002/cncr.26311.
15. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010; 5: 1734-40.
16. Lee C, Kang KH, Koh Y, Chang J, Chung HS, Park SK, Yoo K, Song JS. Characteristics of lung cancer in Korea, 1997. Lung Cancer 2000; 30: 15-22.